Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.29B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.08M
Average 3.00M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +0.2% | +80.5% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +0.2% over three years. Forward estimates point to Revenue at +80.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Glaukos Corporation NYSE:GKOS | $14.55B | $245.72 | Not rated | -39.0 | +150.11% |
Bausch + Lomb Corporation NYSE:BLCO | $7.54B | $21.09 | Overvalued | -24.2 | +42.10% |
Kodiak Sciences Inc. NASDAQ:KOD | $6.99B | $111.19 | Not rated | -9.6 | +399.74% |
STAAR Surgical Company NASDAQ:STAA | $1.32B | $26.39 | Not rated | -68.3 | -8.48% |
Harrow Health, Inc. NASDAQ:HROW | $1.13B | $30.12 | Overvalued | -104.7 | -14.68% |
SpyGlass Pharma, Inc. Common Stock NASDAQ:SGP | $1.10B | $32.88 | Not rated | -14.1 | — |
Oculis Holding AG NASDAQ:OCS | $471.63M | $7.64 | Not rated | -5.5 | -61.29% |
Ocugen, Inc. NASDAQ:OCGN | $280.88M | $0.83 | Not rated | -5.6 | -33.98% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $100.54M | $0.41 | Not rated | -2.1 | -78.67% |
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | $25.66M | $0.31 | Not rated | -4.2 | -78.08% |
Continue the stock analysis
Jump to another research area for this company.